80
Participants
Start Date
December 15, 2022
Primary Completion Date
September 6, 2026
Study Completion Date
April 1, 2027
INT-787
Blinded Study Drug
Placebo
Placebo
RECRUITING
Columbia University Medical Center/New York Presbyterian Hospital, New York
RECRUITING
Northwell Health Center for Liver Disease and Transplantation, Manhasset
RECRUITING
Hospital of the University of Pennsylvania, Philadelphia
RECRUITING
Mercy Medical Center, Baltimore
RECRUITING
VCU Health Clinical Research Services Unit, Richmond
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Hopital Rangueil, Toulouse
RECRUITING
Clinical Translational Research Site, Miami
RECRUITING
Tampa General Medical Group, Tampa
RECRUITING
Vanderbilt Digestive Disease Center, Nashville
RECRUITING
Henry Ford Health System, Detroit
RECRUITING
CHU Angers, Angers
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Hopital Claude Huriez, Lille
RECRUITING
Rush University Medical Center, Chicago
RECRUITING
Hopital Pitie Salpetriere, Paris
RECRUITING
The Liver Institute at Methodist Dallas Medical Center, Dallas
RECRUITING
Parkland Health and Hospital System, Dallas
RECRUITING
University of Texas Southwestern Medical Center, Dallas
NOT_YET_RECRUITING
Baylor College of Medicine, Houston
RECRUITING
University of Utah Hospital, Salt Lake City
RECRUITING
Hopital Beaujon, Clichy
RECRUITING
Stanford Healthcare, Palo Alto
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
UMass Memorial Medical Center, Worcester
WITHDRAWN
Rutgers-New Jersey Medical School, Newark
RECRUITING
Cambridge University NHS Foundation Trust, Cambridge
RECRUITING
Imperial College Healthcare NHS Trust, London
RECRUITING
King's College Hospital, London
RECRUITING
University Hospitals Plymouth NHS Trust, Plymouth
RECRUITING
Royal Free Hospital, London
Lead Sponsor
Intercept Pharmaceuticals
INDUSTRY